XML 70 R57.htm IDEA: XBRL DOCUMENT v3.25.1
Fair Value Measurements - Additional Information (Details)
 3 Months Ended 12 Months Ended
Mar. 31, 2024
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
position
May 08, 2024
USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Net impairment charge   $ 6,772,000    
Impairment charge   0 $ 0  
Contingent consideration, non-current   632,000 1,172,000  
Contingent consideration, current     3,300,000  
Adjustment in the CVR liability     $ 900,000  
Positions that were in unrealized loss positions | position     9  
Remaining contractual maturities of available-for-sale securities     1 year  
Average maturity of investments upon acquisition     9 months  
Surface Acquisition        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Fair value of the contingent consideration $ 3,800,000      
Contingent consideration, non-current   500,000    
Contingent consideration, current 0      
Novartis Institutes        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Impairment charge 10,600,000      
Novartis Institutes | Surface Acquisition        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Net impairment charge $ 6,800,000      
Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration] Selling, General and Administrative Expense      
Impairment charge $ 10,600,000      
Royalty Fee Derivative Liability        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Fair value of the Royalty Fee Derivative   13,600,000   $ 9,200,000
Charge recorded   $ 4,400,000